News | July 20, 2023
M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
CMOs showed an increasing reluctance to take on debt in 2022
CMOs showed an increasing reluctance to take on debt in 2022
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Approval to dramatically change CAR-T therapies landscape
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Advances clinical research capabilities with leading regulatory grade registries platform
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
